JP2016518328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016518328A5 JP2016518328A5 JP2016501667A JP2016501667A JP2016518328A5 JP 2016518328 A5 JP2016518328 A5 JP 2016518328A5 JP 2016501667 A JP2016501667 A JP 2016501667A JP 2016501667 A JP2016501667 A JP 2016501667A JP 2016518328 A5 JP2016518328 A5 JP 2016518328A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- alkoxy
- alkyl
- gene
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361777427P | 2013-03-12 | 2013-03-12 | |
| US61/777,427 | 2013-03-12 | ||
| PCT/US2014/024885 WO2014165232A1 (en) | 2013-03-12 | 2014-03-12 | Compounds for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016518328A JP2016518328A (ja) | 2016-06-23 |
| JP2016518328A5 true JP2016518328A5 (enExample) | 2017-04-13 |
Family
ID=51659101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501667A Pending JP2016518328A (ja) | 2013-03-12 | 2014-03-12 | 癌治療のための化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US9713612B2 (enExample) |
| EP (1) | EP2968348A4 (enExample) |
| JP (1) | JP2016518328A (enExample) |
| KR (1) | KR20150125665A (enExample) |
| CN (1) | CN105142641A (enExample) |
| AU (1) | AU2014248568B2 (enExample) |
| CA (1) | CA2905830C (enExample) |
| WO (1) | WO2014165232A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3009148B1 (en) | 2007-07-02 | 2018-08-22 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
| EP3401329A1 (en) | 2011-07-15 | 2018-11-14 | OncoMed Pharmaceuticals, Inc. | Rspo binding agents and uses thereof |
| CN104379583B (zh) * | 2012-06-15 | 2016-06-08 | 广州源生医药科技有限公司 | 作为wnt信号传导抑制剂的化合物、组合物及其应用 |
| JP6335896B2 (ja) | 2012-07-13 | 2018-05-30 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｒｓｐｏ３結合剤およびその使用法 |
| CN105142641A (zh) | 2013-03-12 | 2015-12-09 | 广州源生医药科技有限公司 | 用于治疗癌症的化合物 |
| CN105348298B (zh) * | 2014-07-04 | 2019-03-19 | 沈阳中化农药化工研发有限公司 | 取代芳基吡啶类化合物及其用途 |
| CA2961374A1 (en) | 2014-09-16 | 2016-03-24 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| MA41123A (fr) * | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | Polythérapie pour le traitement du cancer |
| CN107708699A (zh) * | 2015-05-26 | 2018-02-16 | 源生公司 | 肿瘤生物标志物及其应用 |
| WO2016196218A1 (en) | 2015-05-31 | 2016-12-08 | Curegenix Corporation | Combination compositions for immunotherapy |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| CN105254613A (zh) * | 2015-10-08 | 2016-01-20 | 苏州云轩医药科技有限公司 | 具有Wnt信号通路抑制活性的杂环化合物及其应用 |
| WO2017062688A1 (en) * | 2015-10-08 | 2017-04-13 | Suzhou Yunxuan Yiyao Keji Youxian Gongsi | Wnt signaling pathway inhibitors and therapeutic applications thereof |
| US10450300B2 (en) | 2015-10-08 | 2019-10-22 | Suzhou Yunxuan Yiyao Keji Youxian Gongsi | Wnt signaling pathway inhibitors and therapeutic applications thereof |
| WO2017095918A2 (en) * | 2015-12-01 | 2017-06-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancer using rspo3 antagonists |
| WO2017162611A1 (en) * | 2016-03-21 | 2017-09-28 | Astrazeneca Ab | Quinoline-3-carboxamide compounds and their use in treating cancer |
| WO2017167150A1 (zh) * | 2016-03-31 | 2017-10-05 | 苏州云轩医药科技有限公司 | 一种3-氟吡啶杂环化合物及其应用 |
| KR102476709B1 (ko) | 2016-11-21 | 2022-12-09 | 나노스트링 테크놀로지스, 인크. | 화학적 조성물 및 이것을 사용하는 방법 |
| JP7419068B2 (ja) * | 2016-12-21 | 2024-01-22 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 悪性腫瘍を特定するためのキット及びその使用 |
| US10407424B2 (en) * | 2017-03-30 | 2019-09-10 | Genentech, Inc. | Naphthyridines as inhibitors of HPK1 |
| CN107441045B (zh) | 2017-07-21 | 2018-10-19 | 广州源生医药科技有限公司 | 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法 |
| WO2019071073A1 (en) | 2017-10-06 | 2019-04-11 | Forma Therapeutics, Inc. | INHIBITION OF THE SPECIFIC PEPTIDASE OF UBIQUITIN |
| EP3794146B1 (en) | 2018-05-14 | 2025-12-10 | Bruker Spatial Biology, Inc. | Method for identifying a predetermined nucleotide sequence |
| ES2988920T3 (es) | 2018-05-17 | 2024-11-22 | Forma Therapeutics Inc | Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina |
| CN108685923A (zh) * | 2018-06-07 | 2018-10-23 | 广州源生医药科技有限公司 | Wnt信号通路抑制剂在治疗LGR5阳性癌症中的应用 |
| US10961534B2 (en) | 2018-07-13 | 2021-03-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating porphyria |
| AU2019356011B2 (en) | 2018-10-05 | 2025-02-06 | Forma Therapeutics, Inc. | Fused pyrrolines which act as Ubiquitin-Specific Protease 30 (USP30) inhibitors |
| WO2021004467A1 (zh) * | 2019-07-08 | 2021-01-14 | 南京明德新药研发有限公司 | 作为porcupine抑制剂的化合物及其应用 |
| EP4238974A4 (en) * | 2020-10-28 | 2024-10-23 | Adlai Nortye Biopharma Co., Ltd. | HIGH ACTIVITY WNT PATHWAY INHIBITOR COMPOUND |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999011622A1 (en) * | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Amino-substituted compounds, methods, and compositions for inhibiting parp activity |
| US7342115B2 (en) * | 2002-11-08 | 2008-03-11 | Neurogen Corporation | 3-substituted-6-aryl pyridines |
| EP1673475B1 (en) * | 2003-10-10 | 2010-04-28 | Deutsches Krebsforschungszentrum | Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins) and/or wnt |
| US7452887B2 (en) * | 2004-06-04 | 2008-11-18 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| CA2593578C (en) * | 2005-01-07 | 2013-11-05 | Emory University | Cxcr4 antagonists for the treatment of medical disorders |
| WO2008086462A2 (en) * | 2007-01-11 | 2008-07-17 | Wyeth | AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| CN102573473B (zh) * | 2009-06-09 | 2015-05-27 | 加利福尼亚资本权益有限责任公司 | 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物 |
| CN102558173B (zh) | 2010-12-31 | 2015-05-20 | 广州源生医药科技有限公司 | 抑制wnt信号传导的化合物、组合物及其应用 |
| ES2797533T3 (es) | 2012-02-28 | 2020-12-02 | Novartis Ag | Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43 |
| CN104379583B (zh) | 2012-06-15 | 2016-06-08 | 广州源生医药科技有限公司 | 作为wnt信号传导抑制剂的化合物、组合物及其应用 |
| CN105142641A (zh) | 2013-03-12 | 2015-12-09 | 广州源生医药科技有限公司 | 用于治疗癌症的化合物 |
| CN107708699A (zh) | 2015-05-26 | 2018-02-16 | 源生公司 | 肿瘤生物标志物及其应用 |
-
2014
- 2014-03-12 CN CN201480013734.1A patent/CN105142641A/zh active Pending
- 2014-03-12 JP JP2016501667A patent/JP2016518328A/ja active Pending
- 2014-03-12 US US14/772,337 patent/US9713612B2/en active Active
- 2014-03-12 WO PCT/US2014/024885 patent/WO2014165232A1/en not_active Ceased
- 2014-03-12 EP EP14778108.2A patent/EP2968348A4/en not_active Withdrawn
- 2014-03-12 KR KR1020157024496A patent/KR20150125665A/ko not_active Withdrawn
- 2014-03-12 AU AU2014248568A patent/AU2014248568B2/en not_active Ceased
- 2014-03-12 CA CA2905830A patent/CA2905830C/en active Active
-
2017
- 2017-06-08 US US15/617,988 patent/US10238652B2/en active Active
-
2019
- 2019-01-29 US US16/261,353 patent/US10660889B2/en active Active